Technology

Citius Pharmaceuticals

$1.22
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.04 (-3.17%) Today
$0.00 (0.00%) As of 11:58 AM UTC after-hours

Why Robinhood?

You can buy or sell CTXR and other stocks, options, and ETFs commission-free!

About CTXR

Citius Pharmaceuticals, Inc. Common Stock, also called Citius Pharmaceuticals, is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products, with a focus on anti-infectives and cancer care. It is currently advancing three proprietary product candidates: Mino-Lok, which is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections; CITI-002, which provides anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids; and CITI-101, which is a bio-absorbable film impregnated with minocycline and rifampin for reducing acute inflammation and microbial colonization of breast tissue expanders used in breast reconstruction surgeries following mastectomies. The company was founded by Ralph Montrone on January 23, 2007 and is headquartered in Cranford, NJ. The listed name for CTXR is Citius Pharmaceuticals, Inc. Common Stock.

CEO
Myron Z. Holubiak
Employees
10
Headquarters
Cranford, New Jersey
Founded
2007
Market Cap
65.65M
Price-Earnings Ratio
—
Dividend Yield
—
Average Volume
1.73M
High Today
$1.26
Low Today
$1.18
Open Price
$1.23
Volume
1.51M
52 Week High
$1.97
52 Week Low
$0.415

Collections

CTXR Earnings

-$0.16
-$0.11
-$0.05
$0.00
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Q4 FY20
Q1 FY21
Estimated
— per share
Actual
Expected Feb 11, Pre-Market

You May Also Like

FSDC
All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, a registered broker-dealer and Member SIPC. Full disclosure